Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011.

Tsai H, Lee J, Hedlin H, Zamanian RT, de Jesus Perez VA.

ERJ Open Res. 2019 Oct 15;5(4). pii: 00017-2019. doi: 10.1183/23120541.00017-2019. eCollection 2019 Oct.

2.

Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA.

Am J Respir Crit Care Med. 2019 Sep 12. doi: 10.1164/rccm.201903-0656CI. [Epub ahead of print]

PMID:
31513751
3.

Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Tian W, Jiang X, Sung YK, Shuffle E, Wu TH, Kao PN, Tu AB, Dorfmüller P, Cao A, Wang L, Peng G, Kim Y, Zhang P, Chappell J, Pasupneti S, Dahms P, Maguire P, Chaib H, Zamanian R, Peters-Golden M, Snyder MP, Voelkel NF, Humbert M, Rabinovitch M, Nicolls MR.

Circulation. 2019 Oct 22;140(17):1409-1425. doi: 10.1161/CIRCULATIONAHA.119.040629. Epub 2019 Aug 29.

PMID:
31462075
4.

Development and Performance of the Pulmonary Embolism Result Forecast Model (PERFORM) for Computed Tomography Clinical Decision Support.

Banerjee I, Sofela M, Yang J, Chen JH, Shah NH, Ball R, Mushlin AI, Desai M, Bledsoe J, Amrhein T, Rubin DL, Zamanian R, Lungren MP.

JAMA Netw Open. 2019 Aug 2;2(8):e198719. doi: 10.1001/jamanetworkopen.2019.8719.

5.

EXPRESS: Myocardial Bridge - An Unrecognized Cause of Chest Pain in Pulmonary Arterial Hypertension.

Rajmohan D, Sung YK, Kudelko K, Perez VAJ, Haddad F, Tremmel J, Schnittger I, Zamanian RT, Spiekerkoetter EF.

Pulm Circ. 2019 Jun 12:2045894019860738. doi: 10.1177/2045894019860738. [Epub ahead of print] No abstract available.

PMID:
31187693
6.

Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension.

Sweatt AJ, Hedlin HK, Balasubramanian V, Hsi A, Blum LK, Robinson WH, Haddad F, Hickey PM, Condliffe R, Lawrie A, Nicolls MR, Rabinovitch M, Khatri P, Zamanian RT.

Circ Res. 2019 Mar 15;124(6):904-919. doi: 10.1161/CIRCRESAHA.118.313911.

7.

Low-grade albuminuria in pulmonary arterial hypertension.

Nickel NP, de Jesus Perez VA, Zamanian RT, Fessel JP, Cogan JD, Hamid R, West JD, de Caestecker MP, Yang H, Austin ED.

Pulm Circ. 2019 Apr-Jun;9(2):2045894018824564. doi: 10.1177/2045894018824564.

8.

Clinical trial design and new therapies for pulmonary arterial hypertension.

Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801908. doi: 10.1183/13993003.01908-2018. Print 2019 Jan.

9.

Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.

PMID:
30312106
10.

The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension.

Taylor S, Dirir O, Zamanian RT, Rabinovitch M, Thompson AAR.

Front Med (Lausanne). 2018 Aug 3;5:217. doi: 10.3389/fmed.2018.00217. eCollection 2018. Review.

11.

Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients.

McCullough M, Kholdani C, Zamanian RT.

Clin Chest Med. 2018 Sep;39(3):483-492. doi: 10.1016/j.ccm.2018.04.002. Review.

PMID:
30122173
12.

Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension.

Abbasi Y, Jabbari J, Jabbari R, Glinge C, Izadyar SB, Spiekerkoetter E, Zamanian RT, Carlsen J, Tfelt-Hansen J.

Mol Genet Genomic Med. 2018 Sep;6(5):835-844. doi: 10.1002/mgg3.452. Epub 2018 Aug 6. Review.

13.

Methamphetamine and the risk of pulmonary arterial hypertension.

Ramirez RL 3rd, Perez VJ, Zamanian RT.

Curr Opin Pulm Med. 2018 Sep;24(5):416-424. doi: 10.1097/MCP.0000000000000513. Review.

14.

Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension.

French S, Amsallem M, Ouazani N, Li S, Kudelko K, Zamanian RT, Haddad F, Chung L.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018788268. doi: 10.1177/2045894018788268. Epub 2018 Jun 25.

15.

Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?

Leary PJ, Kolb TM, Maron BA, Tedford RJ, Zamanian RT.

Int J Cardiol. 2018 Aug 1;264:188. doi: 10.1016/j.ijcard.2018.03.130. No abstract available.

PMID:
29776569
16.

Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.

Duarte JD, Kansal M, Desai AA, Riden K, Arwood MJ, Yacob AA, Stamos TD, Cavallari LH, Zamanian RT, Shah SJ, Machado RF.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018773049. doi: 10.1177/2045894018773049.

17.

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.

Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB.

Chest. 2018 Oct;154(4):848-861. doi: 10.1016/j.chest.2018.04.027. Epub 2018 Apr 26.

18.

H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program.

Leary PJ, Hess E, Barón AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, Zamanian RT, Lahm T.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1638-1641. doi: 10.1164/rccm.201801-0048LE. No abstract available.

19.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

20.

Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Orcholski ME, Yuan K, Rajasingh C, Tsai H, Shamskhou EA, Dhillon NK, Voelkel NF, Zamanian RT, de Jesus Perez VA.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L967-L983. doi: 10.1152/ajplung.00553.2017. Epub 2018 Feb 8.

21.

Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension.

Blum LK, Cao RRL, Sweatt AJ, Bill M, Lahey LJ, Hsi AC, Lee CS, Kongpachith S, Ju CH, Mao R, Wong HH, Nicolls MR, Zamanian RT, Robinson WH.

Eur J Immunol. 2018 May;48(5):874-884. doi: 10.1002/eji.201747460. Epub 2018 Feb 22.

22.

Stimulants and Pulmonary Arterial Hypertension: An Update.

Ramirez RL 3rd, De Jesus Perez V, Zamanian RT.

Adv Pulm Hypertens. 2018;17(2):49-54. doi: 10.21693/1933-088X-17.2.49.

23.

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study.

Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, Hulme OL, Pullins EH, Corona-Villalobos CP, Zamanian RT, Minai OA, Girgis RE, Chin K, Khair R, Damico RL, Kolb TM, Mathai SC, Hassoun PM.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217748307. doi: 10.1177/2045893217748307. Epub 2017 Dec 18.

24.

Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database.

Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA.

PLoS One. 2017 Nov 9;12(11):e0187734. doi: 10.1371/journal.pone.0187734. eCollection 2017.

25.

Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Talwar A, Garcia JGN, Tsai H, Moreno M, Lahm T, Zamanian RT, Machado R, Kawut SM, Selej M, Mathai S, D'Anna LH, Sahni S, Rodriquez EJ, Channick R, Fagan K, Gray M, Armstrong J, Rodriguez Lopez J, de Jesus Perez V; Pulmonary Circulation Assembly.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):e32-e47. doi: 10.1164/rccm.201709-1821ST. Review.

26.

Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.

Saito T, Miyagawa K, Chen SY, Tamosiuniene R, Wang L, Sharpe O, Samayoa E, Harada D, Moonen JAJ, Cao A, Chen PI, Hennigs JK, Gu M, Li CG, Leib RD, Li D, Adams CM, Del Rosario PA, Bill M, Haddad F, Montoya JG, Robinson WH, Fantl WJ, Nolan GP, Zamanian RT, Nicolls MR, Chiu CY, Ariza ME, Rabinovitch M.

Circulation. 2017 Nov 14;136(20):1920-1935. doi: 10.1161/CIRCULATIONAHA.117.027589. Epub 2017 Sep 21.

27.

Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.

Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. doi: 10.1164/rccm.201705-0943OC.

28.

Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.

Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, Zamanian RT.

Eur Respir J. 2017 Sep 11;50(3). pii: 1602449. doi: 10.1183/13993003.02449-2016. Print 2017 Sep.

29.

Load Adaptability in Patients With Pulmonary Arterial Hypertension.

Amsallem M, Boulate D, Aymami M, Guihaire J, Selej M, Huo J, Denault AY, McConnell MV, Schnittger I, Fadel E, Mercier O, Zamanian RT, Haddad F.

Am J Cardiol. 2017 Sep 1;120(5):874-882. doi: 10.1016/j.amjcard.2017.05.053. Epub 2017 Jun 16.

PMID:
28705377
30.

Kidney dysfunction in patients with pulmonary arterial hypertension.

Nickel NP, O'Leary JM, Brittain EL, Fessel JP, Zamanian RT, West JD, Austin ED.

Pulm Circ. 2017 Mar 13;7(1):38-54. doi: 10.1086/690018. eCollection 2017 Mar. Review.

31.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE. No abstract available.

32.

Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models.

Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, Mercier O, Fadel E, Schnittger I, McConnell MV, Rabinovitch M, Zamanian RT, Haddad F.

Circ Cardiovasc Imaging. 2017 Jun;10(6). pii: e005771. doi: 10.1161/CIRCIMAGING.116.005771.

33.

Identification of Pulmonary Hypertension Caused by Left-Sided Heart Disease (World Health Organization Group 2) Based on Cardiac Chamber Volumes Derived From Chest CT Imaging.

Aviram G, Rozenbaum Z, Ziv-Baran T, Berliner S, Topilsky Y, Fleischmann D, Sung YK, Zamanian RT, Guo HH.

Chest. 2017 Oct;152(4):792-799. doi: 10.1016/j.chest.2017.04.184. Epub 2017 May 12.

PMID:
28506612
34.

Leukotriene B4 antagonism ameliorates experimental lymphedema.

Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH, Zamanian RT, Dhillon GS, Voelkel NF, Peters-Golden M, Kitajewski J, Dixon JB, Nicolls MR.

Sci Transl Med. 2017 May 10;9(389). pii: eaal3920. doi: 10.1126/scitranslmed.aal3920.

PMID:
28490670
35.

Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension.

Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD, Morisseau C, Hammock BD, Hong EM, Alexandrova L, Alastalo TP, Berry G, Zamanian RT, de Jesus Perez VA.

Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L252-L266. doi: 10.1152/ajplung.00453.2016. Epub 2017 May 4.

36.

What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension.

Leary PJ, Kang S, Kolb TM, Maron BA, Ralph DD, Rao Y, Tedford RJ, Zamanian RT.

Int J Cardiol. 2017 Aug 1;240:386-391. doi: 10.1016/j.ijcard.2017.04.016. Epub 2017 Apr 6.

PMID:
28412029
37.

Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease.

Amsallem M, Boulate D, Kooreman Z, Zamanian RT, Fadel G, Schnittger I, Fadel E, McConnell MV, Dhillon G, Mercier O, Haddad F.

Int J Cardiovasc Imaging. 2017 Jun;33(6):825-835. doi: 10.1007/s10554-017-1069-3. Epub 2017 Jan 24.

PMID:
28120156
38.

Left Atrium Maximal Axial Cross-Sectional Area is a Specific Computed Tomographic Imaging Biomarker of World Health Organization Group 2 Pulmonary Hypertension.

Jivraj K, Bedayat A, Sung YK, Zamanian RT, Haddad F, Leung AN, Rosenberg J, Guo HH.

J Thorac Imaging. 2017 Mar;32(2):121-126. doi: 10.1097/RTI.0000000000000252.

PMID:
28009778
39.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):106-113. Epub 2016 Nov 10.

PMID:
27908301
40.

An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

Zamanian RT, Levine DJ, Bourge RC, De Souza SA, Rosenzweig EB, Alnuaimat H, Burger C, Mathai SC, Leedom N, DeAngelis K, Lim A, De Marco T.

Pulm Circ. 2016 Sep;6(3):329-37. doi: 10.1086/688059.

41.

The Authors Reply.

Haddad F, Vonk-Noordegraaf A, Zamanian RT.

JACC Cardiovasc Imaging. 2016 May;9(5):630. doi: 10.1016/j.jcmg.2015.09.016. Epub 2016 Feb 17. No abstract available.

42.

Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G.

Circulation. 2016 Mar 29;133(13):1240-8. doi: 10.1161/CIRCULATIONAHA.115.020207. Epub 2016 Feb 12.

43.

Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography.

Amsallem M, Sternbach JM, Adigopula S, Kobayashi Y, Vu TA, Zamanian R, Liang D, Dhillon G, Schnittger I, McConnell MV, Haddad F.

J Am Soc Echocardiogr. 2016 Feb;29(2):93-102. doi: 10.1016/j.echo.2015.11.001. Epub 2015 Dec 11.

PMID:
26691401
44.

Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.

Qian J, Tian W, Jiang X, Tamosiuniene R, Sung YK, Shuffle EM, Tu AB, Valenzuela A, Jiang S, Zamanian RT, Fiorentino DF, Voelkel NF, Peters-Golden M, Stenmark KR, Chung L, Rabinovitch M, Nicolls MR.

Hypertension. 2015 Dec;66(6):1227-1239. doi: 10.1161/HYPERTENSIONAHA.115.06370. Epub 2015 Oct 5.

45.

Prognostic utility of right atrial emptying fractions in pulmonary arterial hypertension.

Brunner NW, Haddad F, Kobayashi Y, Hsi A, Swiston JR, Gin KG, Zamanian RT.

Pulm Circ. 2015 Sep;5(3):473-80. doi: 10.1086/682218.

46.

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

47.

Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT.

Am J Respir Crit Care Med. 2015 Jul 15;192(2):254-7. doi: 10.1164/rccm.201411-2061LE. No abstract available.

48.

Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa domesticus).

Brunner NW, Zamanian RT, Ikeno F, Mitsutake Y, Connolly AJ, Shuffle E, Yuan K, Orcholski M, Lyons J, de Jesus Perez VA.

Comp Med. 2015 Jun;65(3):217-24.

49.

RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Rhodes CJ, Im H, Cao A, Hennigs JK, Wang L, Sa S, Chen PI, Nickel NP, Miyagawa K, Hopper RK, Tojais NF, Li CG, Gu M, Spiekerkoetter E, Xian Z, Chen R, Zhao M, Kaschwich M, Del Rosario PA, Bernstein D, Zamanian RT, Wu JC, Snyder MP, Rabinovitch M.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):356-66. doi: 10.1164/rccm.201408-1528OC.

50.

Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension.

Haddad F, Spruijt OA, Denault AY, Mercier O, Brunner N, Furman D, Fadel E, Bogaard HJ, Schnittger I, Vrtovec B, Wu JC, de Jesus Perez V, Vonk-Noordegraaf A, Zamanian RT.

JACC Cardiovasc Imaging. 2015 Jun;8(6):627-38. doi: 10.1016/j.jcmg.2014.12.029. Epub 2015 May 14.

Supplemental Content

Loading ...
Support Center